全文获取类型
收费全文 | 3104篇 |
免费 | 206篇 |
国内免费 | 1篇 |
专业分类
3311篇 |
出版年
2023年 | 20篇 |
2022年 | 28篇 |
2021年 | 74篇 |
2020年 | 25篇 |
2019年 | 49篇 |
2018年 | 36篇 |
2017年 | 42篇 |
2016年 | 61篇 |
2015年 | 143篇 |
2014年 | 160篇 |
2013年 | 204篇 |
2012年 | 233篇 |
2011年 | 240篇 |
2010年 | 162篇 |
2009年 | 135篇 |
2008年 | 182篇 |
2007年 | 220篇 |
2006年 | 195篇 |
2005年 | 168篇 |
2004年 | 181篇 |
2003年 | 151篇 |
2002年 | 127篇 |
2001年 | 22篇 |
2000年 | 24篇 |
1999年 | 23篇 |
1998年 | 23篇 |
1997年 | 30篇 |
1996年 | 15篇 |
1995年 | 20篇 |
1994年 | 18篇 |
1993年 | 14篇 |
1992年 | 26篇 |
1991年 | 14篇 |
1990年 | 20篇 |
1989年 | 11篇 |
1988年 | 13篇 |
1987年 | 14篇 |
1986年 | 9篇 |
1985年 | 11篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 25篇 |
1981年 | 19篇 |
1980年 | 17篇 |
1979年 | 12篇 |
1978年 | 8篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1975年 | 6篇 |
1974年 | 5篇 |
排序方式: 共有3311条查询结果,搜索用时 15 毫秒
91.
Luc Friboulet Sophie Postel-Vinay Tony Sourisseau Julien Adam Annabelle Stoclin Florence Ponsonnailles Nicolas Dorvault Frédéric Commo Patrick Saulnier Sophie Salome-Desmoulez Géraldine Pottier Fabrice André Guido Kroemer Jean Charles Soria Ken André Olaussen 《Cell cycle (Georgetown, Tex.)》2013,12(20):3298-3306
ERCC1 (excision repair cross-complementation group 1) plays essential roles in the removal of DNA intrastrand crosslinks by nucleotide excision repair, and that of DNA interstrand crosslinks by the Fanconi anemia (FA) pathway and homology-directed repair processes (HDR). The function of ERCC1 thus impacts on the DNA damage response (DDR), particularly in anticancer therapy when DNA damaging agents are employed. ERCC1 expression has been proposed as a predictive biomarker of the response to platinum-based therapy. However, the assessment of ERCC1 expression in clinical samples is complicated by the existence of 4 functionally distinct protein isoforms, which differently impact on DDR. Here, we explored the functional competence of each ERCC1 protein isoform and obtained evidence that the 202 isoform is the sole one endowed with ERCC1 activity in DNA repair pathways. The ERCC1 isoform 202 interacts with RPA, XPA, and XPF, and XPF stability requires expression of the ERCC1 202 isoform (but none of the 3 others). ERCC1-deficient non-small cell lung cancer cells show abnormal mitosis, a phenotype reminiscent of the FA phenotype that can be rescued by isoform 202 only. Finally, we could not observe any dominant-negative interaction between ERCC1 isoforms. These data suggest that the selective assessment of the ERCC1 isoform 202 in clinical samples should accurately reflect the DDR-related activity of the gene and hence constitute a useful biomarker for customizing anticancer therapies. 相似文献
92.
93.
Luigi Di Luigi Mariangela Sottili Cristina Antinozzi Gabriella Barbara Vannelli Francesco Romanelli Valeria Riccieri Guido Valesini Andrea Lenzi Clara Crescioli 《PloS one》2013,8(10)
Objective
This study aims to investigate in vitro the effect of the VDR agonist BXL-01-0029 onto IFNγ/TNFα-induced CXCL10 secretion by human skeletal muscle cells compared to elocalcitol (VDR agonist), methylprednisolone, methotrexate, cyclosporin A, infliximab and leflunomide; to assess in vivo circulating CXCL10 level in subjects at time of diagnosis with IMs, before therapy, together with TNFα, IFNγ, IL-8, IL-6, MCP-1, MIP-1β and IL-10, vs. healthy subjects.Methods
Human fetal skeletal muscle cells were used for in vitro studies; ELISA and Bio-Plex were used to measure cell supernatant and IC50 determination or serum cytokines; Western blot and Bio-Plex were for cell signaling analysis.Results
BXL-01-0029 decreased with the highest potency IFNγ/TNFα-induced CXCL10 protein secretion and targeted cell signaling downstream of TNFα in human skeletal muscle cells; CXCL10 level was the highest in sera of subjects diagnosed with IMs before therapy and the only one significantly different vs. healthy controls.Conclusions
Our in vitro and in vivo data, while confirm the relevance of CXCL10 in IMs, suggested BXL-01-0029 as a novel pharmacological tool for IM treatment, hypothetically to be used in combination with the current immunosuppressants to minimize side effects. 相似文献94.
Carmen Methner Guido Buonincontri Chou-Hui Hu Ana Vujic Axel Kretschmer Stephen Sawiak Adrian Carpenter Johannes-Peter Stasch Thomas Krieg 《PloS one》2013,8(12)
Aim
Stimulation of the nitric oxide (NO) – soluble guanylate (sGC) - protein kinase G (PKG) pathway confers protection against acute ischaemia/reperfusion injury, but more chronic effects in reducing post-myocardial infarction (MI) heart failure are less defined. The aim of this study was to not only determine whether the sGC stimulator riociguat reduces infarct size but also whether it protects against the development of post-MI heart failure.Methods and Results
Mice were subjected to 30 min ischaemia via ligation of the left main coronary artery to induce MI and either placebo or riociguat (1.2 µmol/l) were given as a bolus 5 min before and 5 min after onset of reperfusion. After 24 hours, both, late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) and 18F-FDG-positron emission tomography (PET) were performed to determine infarct size. In the riociguat-treated mice, the resulting infarct size was smaller (8.5±2.5% of total LV mass vs. 21.8%±1.7%. in controls, p = 0.005) and LV systolic function analysed by MRI was better preserved (60.1%±3.4% of preischaemic vs. 44.2%±3.1% in controls, p = 0.005). After 28 days, LV systolic function by echocardiography treated group was still better preserved (63.5%±3.2% vs. 48.2%±2.2% in control, p = 0.004).Conclusion
Taken together, mice treated acutely at the onset of reperfusion with the sGC stimulator riociguat have smaller infarct size and better long-term preservation of LV systolic function. These findings suggest that sGC stimulation during reperfusion therapy may be a powerful therapeutic treatment strategy for preventing post-MI heart failure. 相似文献95.
96.
Annalisa Nuccitelli C. Daniela Rinaudo Barbara Brogioni Roberta Cozzi Mario Ferrer-Navarro Daniel Yero John L. Telford Guido Grandi Xavier Daura Martin Zacharias Domenico Maione 《PLoS computational biology》2013,9(6)
The pilus 2a backbone protein (BP-2a) is one of the most structurally and functionally characterized components of a potential vaccine formulation against Group B Streptococcus. It is characterized by six main immunologically distinct allelic variants, each inducing variant-specific protection. To investigate the molecular determinants driving the variant immunogenic specificity of BP-2a, in terms of single residue contributions, we generated six monoclonal antibodies against a specific protein variant based on their capability to recognize the polymerized pili structure on the bacterial surface. Three mAbs were also able to induce complement-dependent opsonophagocytosis killing of live GBS and target the same linear epitope present in the structurally defined and immunodominant domain D3 of the protein. Molecular docking between the modelled scFv antibody sequences and the BP-2a crystal structure revealed the potential role at the binding interface of some non-conserved antigen residues. Mutagenesis analysis confirmed the necessity of a perfect balance between charges, size and polarity at the binding interface to obtain specific binding of mAbs to the protein antigen for a neutralizing response. 相似文献
97.
Gianpiero Di Leva Claudia Piovan Pierluigi Gasparini Apollinaire Ngankeu Cristian Taccioli Daniel Briskin Douglas G. Cheung Brad Bolon Laura Anderlucci Hansjuerg Alder Gerard Nuovo Meng Li Marilena V. Iorio Marco Galasso Santhanam Ramasamy Guido Marcucci Danilo Perrotti Kimerly A. Powell Anna Bratasz Michela Garofalo Kenneth P. Nephew Carlo M. Croce 《PLoS genetics》2013,9(3)
98.
99.
Wim Martinet Dorien M. Schrijvers Jean-Pierre Timmermans Hidde Bult Guido R.Y. De Meyer 《Autophagy》2013,9(3):386-402
Transmission electron microscopy (TEM) is an indispensable standard method to monitor macroautophagy in tissue samples. Because TEM is time consuming and not suitable for daily routine, many groups try to identify macroautophagy in tissue by conventional immunohistochemistry. The aim of the present study was to evaluate whether immunohistochemical assessment of macroautophagy-related marker proteins such as LC3, ATG5, CTSD/cathepsin D, BECN1/Beclin 1 or SQSTM1/p62 is feasible and autophagy-specific. For this purpose, livers from starved mice were used as a model because hepatocytes are highly sensitive to autophagy induction. ATG7-deficient mouse livers served as negative control. Our findings indicate that unambiguous immunodetection of LC3 in paraffin-embedded tissue specimens was hampered due to low in situ levels of this protein. Maximum sensitivity could only be obtained using high-quality, isoform-specific antibodies, such as antibody 5F10, in combination with Envision+ signal amplification. Moreover, LC3 stains were optimal in neutral-buffered formalin-fixed tissue, immersed in citrate buffer during antigen retrieval. However, even when using this methodology, LC3 monitoring required overexpression of the protein, e.g., in GFP-LC3 transgenic mice. This was not only the case for the liver but also for other organs including heart, skeletal muscle, kidney and gut. Immunohistochemical detection of the autophagy-related proteins ATG5, CTSD or BECN1 is not recommendable for monitoring autophagy, due to lack of differential gene expression or doubtful specificity. SQSTM1 accumulated in autophagy-deficient liver, thus it is not a useful marker for tissue with autophagic activity. We conclude that TEM remains an indispensable technique for in situ evaluation of macroautophagy, particularly in clinical samples for which genetic manipulation or other in vitro techniques are not feasible. 相似文献
100.
Sunita S. Balla-Jhagjhoorsingh Davide Corti Leo Heyndrickx Elisabeth Willems Katleen Vereecken David Davis Guido Vanham 《PloS one》2013,8(7)
Immunogen design for HIV-1 vaccines could be based on epitope identification of naturally occurring neutralizing antibodies in infected patients. A tier 2 neutralizing monoclonal antibody (mAb), HJ16 recognizes a new epitope in the CD4 binding site (CD4bs) region that only partially overlaps with the b12 epitope. We aimed to identify the critical binding site by resistance induction in a sensitive primary CRF02_AG strain. In four independent dose-escalation studies, the N276D mutation was consistently the only alteration found and it was confirmed to be responsible for resistance to HJ16 by site-directed mutagenesis in envelopes (envs) of the homologous CRF02_AG, as well as of a subtype A and a subtype C primary isolate. This mutation removes an N-linked glycosylation site. The effect of N276D was very selective, as it failed to confer resistance to a range of other entry inhibitors. Remarkably, sensitivity to the CD4bs VRC01 and VRC03 mAbs was increased in the N276D mutated viruses. These data indicate that binding of the CD4bs specific HJ16 mAb critically depends on the interaction with the N276-glycan, thus indicating that HJ16 is the first glycan dependent CD4bs-specific mAb. 相似文献